Epidermal growth factor receptor and beta-tubulin (EGFR/Tubulin)

The dual target comprising the Epidermal Growth Factor Receptor (EGFR) and beta-tubulin represents a strategic approach in cancer therapy designed to simultaneously inhibit cell signaling and mitosis [1, 2]. EGFR is a transmembrane receptor tyrosine kinase that plays a critical role in cell growth, survival, and differentiation, and its dysregulation is a hallmark of various malignancies, particularly non-small cell lung cancer [7, 9]. Beta-tubulin is a core structural component of microtubules, which are essential for the formation of the mitotic spindle during cell division and for maintaining cellular architecture [1, 5]. Drugs targeting this dual entity, often referred to as dual EGFR/tubulin inhibitors, aim to achieve synergistic antitumor effects by blocking the phosphorylation-dependent signaling pathways of EGFR while concurrently disrupting microtubule dynamics [2, 3]. This multi-targeted mechanism is particularly valuable for overcoming resistance to conventional EGFR tyrosine kinase inhibitors, which often arises from secondary mutations or the activation of alternative survival pathways [4, 6]. By inducing both G2/M phase arrest and apoptosis, these agents offer a potent therapeutic option for treating heterogeneous and drug-resistant tumors [3, 8].

Other names

EGFR/tubulin dual targetEGFR and microtubule dual targetEGFR-tubulinEpidermal growth factor receptor and tubulin

Dual inhibition of EGFR tyrosine kinase activity and tubulin polymerization, leading to disruption of oncogenic signaling and mitotic spindle formation.